**Training Plan Check: Specialist Portfolio in Haematology with Hospital Transfusion practice**

Name: ………………………………………………………. Date training commenced: ……………..

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Standard** | | **Q&A**  **Done / Re-do / complete** | **Evidence**  **Done / Re-do** | **Competency**  **Done / in date** | **Reflective**  **Done** | **Complete** |
| **7.1 Primary investigations of blood and its components.** | | | | | | |
| **7.1a** | Cell counting and haemoglobin concentration measurement. | **□ □ □** | **□ □** | **□ □** | **□** |  |
| **7.1b** | ESR / Plasma viscosity. | **□ □ □** | **□ □** | **□ □** |  |
| **7.1c** | Identification and enumeration of peripheral blood cells by microscopy. | **□ □ □** | **□ □** | **□ □** |  |
| **7.1d** | Infectious Mononucleosis. | **□ □ □** | **□ □** | **□ □** |  |
| **7.1e** | Sickle cell. | **□ □ □** | **□ □** | **□ □** |  |
| **7.1f** | Malaria parasites. | **□ □ □** | **□ □** | **□ □** |  |
| **7.1g** | Haemostasis function. | **□ □ □** | **□ □** | **□ □** |  |
| **7.1h** | Fibrinogen. | **□ □ □** | **□ □** | **□ □** |  |
| **7.1i** | Fibrin degradation products. | **□ □ □** | **□ □** | **□ □** |  |
| **7.1j** | Anticoagulant therapy. | **□ □ □** | **□ □** | **□ □** |  |
| **7.2 Iron deficiency anaemia and iron overload** | | | | | | |
| **7.2a** | Iron deficiency anaemia and iron overload. | **□ □ □** | **□ □** | **□ □** | **□** |  |
| **7.3 Haemolytic anaemia** | | | | | | |
| **7.3a** | Haemolytic anaemia screening tests. | **□ □ □** | **□ □** | **□ □** | **□** |  |
| **Standard** | | **Q&A**  **Set / Done / Re-do** | **Evidence**  **Done / Re-do** | **Competency**  **Done / in date** | **Reflective**  **Done** | **Complete**  **Date** |
| **7.3b** | Inherited and acquired haemolytic anaemia. | **□ □ □** | **□ □** | **□ □** |  |  |
| **7.4 Abnormal haemoglobins and thalassaemia** | | | | | | |
| **7.4a** | Haemoglobin variants (HbS, C, D and E). | **□ □ □** | **□ □** | **□ □** | **□** |  |
| **7.4b** | Imbalanced globin chain production. | **□ □** | **□ □** |  |
| **7.4c** | Unstable haemoglobin. | **□ □** | **□ □** |  |
| **7.5 Megaloblastic anaemia** | | | | | | |
| **7.5a** | Vitamin B12 deficiency. | **□ □ □** | **□ □** | **□ □** | **□** |  |
| **7.5b** | Folate deficiency. | **□ □** | **□ □** |  |
| **7.6 Haematological malignancies** | | | | | | |
| **7.6a** | White cell malignancy. | **□ □ □** | **□ □** | **□ □** | **□** |  |
| **7.6b** | Polycythaemia. | **□ □ □** | **□ □** | **□ □** |  |
| **7.7 Haemostasis abnormalities** | | | | | | |
| **7.7a** | Bleeding disorders. | **□ □ □** | **□ □** | **□ □** | **□** |  |
| **7.7b** | Thrombotic disorders. | **□ □** | **□ □** |  |
| **7.7c** | Lupus anticoagulant. | **□ □** | **□ □** |  |
| **7.8 Hospital transfusion practice** | | | | | | |
| **7.8a** | Routine ABO / D typing and antibody screening. | **□ □ □** | **□ □** | **□ □** | **□** |  |
| **7.8b** | ABO and RhD anomalies. | **□ □ □** | **□ □** | **□ □** |  |
| **7.8c** | Antibody identification. | **□ □ □** | **□ □** | **□ □** |  |
| **Standard** | | **Q&A**  **Set / Done / Re-do** | **Evidence**  **Done / Re-do** | **Competency**  **Done / in date** | **Reflective**  **Done** | **Complete**  **Date** |
| **7.8d** | Red cell phenotyping. | **□ □ □** | **□ □** | **□ □** |  |  |
| **7.8e** | Selection of red cells and components. | **□ □ □** | **□ □** | **□ □** |  |
| **7.8f** | Procedures for establishing compatibility. | **□ □ □** | **□ □** | **□ □** |  |
| **7.8g** | Issuing of blood components and products. | **□ □ □** | **□ □** | **□ □** |  |
| **7.8h** | Blood stocks management. | **□ □ □** | **□ □** | **□ □** |  |
| **7.8i** | Adverse reactions and events in transfusion. | **□ □ □** | **□ □** | **□ □** |  |
| **7.8j** | Antenatal testing and procedures. | **□ □ □** | **□ □** | **□ □** |  |
| **7.8k** | Haemolytic disease of the fetus and newborn. | **□ □ □** | **□ □** | **□ □** |  |
| **7.8l** | Investigation of red cell autoantibodies. | **□ □ □** | **□ □** | **□ □** |  |